Form 4: Acadia Director Sells 1,600 Shares in Pre-Planned Trade

Acadia Pharmaceuticals director Elizabeth A. Garofalo sold 1,600 shares of common stock for approximately $25.98 per share in a pre-planned transaction.

Summary

• Elizabeth A. Garofalo, a Director at Acadia Pharmaceuticals Inc. (ACAD), sold 1,600 shares of common stock.
• The transaction occurred on September 2, 2025.
• The shares were sold at a weighted average price of $25.9753 per share, with individual transaction prices ranging from $25.97 to $25.991.
• Following this transaction, Ms. Garofalo beneficially owns 25,382 shares of Acadia Pharmaceuticals common stock.
• The transaction was executed pursuant to a Rule 10b5-1(c) pre-planned contract or instruction for the purchase or sale of equity securities.

Sentiment

Score: 5

Explanation: Neutral. While an insider sale is generally a slight negative, the transaction was pre-planned under a Rule 10b5-1 plan, which mitigates the negative signal often associated with insider selling. The amount sold is also relatively small compared to the director's remaining holdings.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-scheduled sale rather than an immediate reaction to new, non-public information.

Negatives

• A director selling shares, even if pre-planned, can be perceived as a slight negative signal regarding future stock performance by some investors.
• The sale reduces the director's direct ownership in the company.

Related Party Transactions

• The sale of 1,600 shares of common stock by Director Elizabeth A. Garofalo to the open market constitutes a related party transaction.

Stakeholder Impact

• Shareholders may interpret the sale as a slight negative signal, though this is mitigated by the pre-planned nature of the transaction under a 10b5-1 plan. The reduction in direct insider ownership is minimal relative to the company's overall market capitalization.

Key Dates

Recommendation

The sale by a director, while a reduction in insider ownership, was executed under a pre-planned 10b5-1 arrangement. This suggests a routine portfolio management decision rather than a reaction to adverse company-specific news. The relatively small volume of shares sold (1,600 shares) is unlikely to signal a significant shift in the director's confidence or the company's prospects. Therefore, the filing alone does not warrant a change in investment thesis, and a 'hold' recommendation is appropriate.

Keywords

Acadia Pharmaceuticals, ACAD, insider trading, Form 4, stock sale, director, Elizabeth A. Garofalo, 10b5-1 plan, common stock